On Oct. 25, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had concluded that a booster dose of Spikevax, the Company’s vaccine against COVID-19, at the 50 ﾵg dose level may be considered in people aged 18 years and older at least six months after completion of the primary series.